- Home
- ARHS vs SVRA Comparison
ARHS vs SVRA Comparison
Compare ARHS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | SVRA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 1.1B |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ARHS | SVRA |
|---|---|---|
| Price | $6.89 | $6.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $10.78 | $7.33 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,379,222,000.00 | N/A |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | $430.87 |
| P/E Ratio | $14.30 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $6.17 | $1.89 |
| 52 Week High | $12.97 | $7.01 |
Technical Indicators
Market Signals| Indicator | ARHS | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 64.10 |
| Support Level | $6.17 | $5.86 |
| Resistance Level | $7.61 | $6.49 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | 0.13 | 0.09 |
| Stochastic Oscillator | 87.65 | 90.29 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).